BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
Key insights on breast cancer in Cape Verde
Addressing cancer control challenges in Africa
Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety
TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML
Consolidation treatment delays do not compromise survival in MRD-negative adult ALL
SABCS 2025: Latest developments in multigene testing in early breast cancer
Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC
Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer
Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL
Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer
Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab